Detalhe da pesquisa
1.
Comparison of the reactogenicity and immunogenicity between two-dose mRNA COVID-19 vaccine and inactivated COVID-19 vaccine followed by an mRNA vaccine in children aged 5-11 years.
J Med Virol
; 95(5): e28758, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37212319
2.
Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination.
J Infect Dis
; 226(8): 1372-1381, 2022 10 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35267040
3.
Effects of boosted mRNA and adenoviral-vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination.
J Med Virol
; 94(12): 5713-5722, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35924475
4.
Antibody persistence to diphtheria toxoid, tetanus toxoid, Bordetella pertussis antigens, and Haemophilus influenzae type b following primary and first booster with pentavalent versus hexavalent vaccines.
Hum Vaccin Immunother
; 20(1): 2352909, 2024 Dec 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-38752802
5.
Long-Term Dynamic Changes in Hybrid Immunity over Six Months after Inactivated and Adenoviral Vector Vaccination in Individuals with Previous SARS-CoV-2 Infection.
Vaccines (Basel)
; 12(2)2024 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38400163
6.
Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3-4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination.
Heliyon
; 10(1): e23892, 2024 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38226248
7.
Immunogenicity of the pentavalent DTwP-HB-Hib vaccine (Shan-5) used in the Thai Expanded Program on Immunization compared to the hexavalent DTaP-HB-Hib-IPV and DTwP-HB-Hib (Quinvaxem) vaccines administered to infants at 2, 4, 6 months of age.
Vaccine
; 41(26): 3855-3861, 2023 06 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37202270
8.
Epidemiology and clinical characteristics of severe acute respiratory infections among hospitalized children under 5 years of age in a tertiary care center in Bangkok, Thailand, 2019-2020.
Heliyon
; 9(11): e22300, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-38045212
9.
Neutralizing antibodies against Omicron BA.5 among children with infection alone, vaccination alone, and hybrid immunity.
Int J Infect Dis
; 134: 18-22, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37207716
10.
The Fourth Dose of mRNA COVID-19 Vaccine Following 12 Different Three-Dose Regimens: Safety and Immunogenicity to Omicron BA.4/BA.5.
Vaccines (Basel)
; 11(3)2023 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36992154
11.
SARS-CoV-2 infection- induced seroprevalence among children and associated risk factors during the pre- and omicron-dominant wave, from January 2021 through December 2022, Thailand: A longitudinal study.
PLoS One
; 18(4): e0279147, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37104299
12.
Dynamics of Cytokine, SARS-CoV-2-Specific IgG, and Neutralizing Antibody Levels in COVID-19 Patients Treated with Convalescent Plasma.
Diseases
; 11(3)2023 Aug 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37754308
13.
SARS-CoV-2 Antibody Dynamics after COVID-19 Vaccination and Infection: A Real-World Cross-Sectional Analysis.
Vaccines (Basel)
; 11(7)2023 Jun 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37515001
14.
Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (CovovaxTM) after homologous and heterologous two-dose regimens.
Int J Infect Dis
; 126: 64-72, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36427701
15.
Seroprevalence of SARS-CoV-2 anti-nucleocapsid total Ig, anti-RBD IgG antibodies, and infection in Thailand: a cross-sectional survey from October 2022 to January 2023.
Sci Rep
; 13(1): 15595, 2023 09 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37730917
16.
Safety and Humoral and Cellular Immunogenicity of the BNT162b2 SARS-CoV-2 Vaccine in Liver-Transplanted Adolescents Compared to Healthy Adolescents.
Vaccines (Basel)
; 10(8)2022 Aug 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36016212
17.
Strong Correlations between the Binding Antibodies against Wild-Type and Neutralizing Antibodies against Omicron BA.1 and BA.2 Variants of SARS-CoV-2 in Individuals Following Booster (Third-Dose) Vaccination.
Diagnostics (Basel)
; 12(8)2022 Jul 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-35892491
18.
Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study.
Hum Vaccin Immunother
; 18(1): 2029111, 2022 12 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-35209809
19.
Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine.
Vaccines (Basel)
; 10(1)2022 Jan 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35062747
20.
Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults.
Vaccine
; 40(3): 524-530, 2022 01 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34893344